PureTech News

Press Releases
ALL >
Press Release - 2026-07-13
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Continue
Press Release - 2026-07-02
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Continue
Press Release - 2026-07-02
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Continue
Publications
ALL >
Publications 2026-04-02
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial
Full Article
Publications 2026-03-25
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
Full Article
Publications 2025-05-08
Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
Full Article

@PureTechH